Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022087 · ClinicalTrials.gov registry record · Phase 3
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
A Phase 3 study of Breast Cancer and Osteoporosis, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 439
- Enrollment target
- 20
- Study locations
NCT00022087 is a Phase 3 study of Breast Cancer and Osteoporosis that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 439 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00022087, a Phase 3 study of Breast Cancer and Osteoporosis, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 439 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus calcium and vitamin D to see how well they work in preventing bone loss in women who are receiving adjuvant chemotherapy for breast cancer.
Conditions Studied
Interventions
- DRUG zoledronic acid
- DIETARY_SUPPLEMENT cholecalciferol
- DIETARY_SUPPLEMENT calcium salts
Study Locations (20)
Florida
- Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital - Fort Lauderdale
- Memorial Cancer Institute at Memorial Regional Hospital - Hollywood
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center - Jupiter
- CCOP - Mount Sinai Medical Center - Miami Beach
- Cancer Research Network, Incorporated - Plantation
- Cleveland Clinic Florida - Weston - Weston
California
- Arroyo Grande Community Hospital - Arroyo Grande
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- El Camino Hospital - Mountain View
- Naval Medical Center - San Diego - San Diego
- Veterans Affairs Medical Center - San Diego - San Diego
Delaware
- Kent General Hospital at Bayhealth Medical Center - Dover
- Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
- St. Francis Hospital - Wilmington
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
- Washington Cancer Institute at Washington Hospital Center - Washington D.C.
- Sibley Memorial Hospital - Washington D.C.
Illinois
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2001-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022087
The ClinicalTrials.gov registry entry for NCT00022087 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which zoledronic acid is the first listed.
NCT00022087 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT00022087 about?
NCT00022087 is a clinical study titled "Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer". RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective in preventing bone loss. PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus ...
What is the current status of trial NCT00022087?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2001-12. Estimated completion is 2009-02.
What conditions does trial NCT00022087 study?
This clinical trial studies the following conditions: Breast Cancer, Osteoporosis.
What interventions are being tested in trial NCT00022087?
The interventions under investigation include: zoledronic acid (DRUG), cholecalciferol (DIETARY_SUPPLEMENT), calcium salts (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00022087?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022087 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.